We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-14.83%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.16B
AUM Growth
-$1.15B
Cap. Flow
+$52.2M
Cap. Flow %
1.01%
Top 10 Hldgs %
40.75%
Holding
232
New
16
Increased
80
Reduced
52
Closed
17

Top Buys

Rank Stock Value
1
BDTX icon
Black Diamond Therapeutics
BDTX
+$40.5M
2
FATE icon
Fate Therapeutics
FATE
+$37.4M
3
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$29.7M
4
ESPR
Esperion Therapeutics
ESPR
+$27.1M
5
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$25.4M

Top Sells

Rank Stock Value
1
TDOC icon
Teladoc Health
TDOC
+$63.8M
2
BMY icon
Bristol-Myers Squibb
BMY
+$54M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.7M
4
MRNA icon
Moderna
MRNA
+$22.7M
5
ALGN icon
Align Technology
ALGN
+$18.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.76%
2 Technology 0.56%
3 Industrials 0.54%
4 Communication Services 0.17%
5 Financials 0.08%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AMGN icon
51
Amgen
AMGN
$198B
$26.7M 0.52%
131,573
+91,223
+226% +$19.9M
INSM icon
52
Insmed
INSM
$23.5B
$25.9M 0.5%
1,613,470
+29,910
+2% +$709K
QTTB icon
53
Q32 Bio
QTTB
$346M
$25.1M 0.49%
89,562
– –
VYGR icon
54
Voyager Therapeutics
VYGR
$192M
$24.9M 0.48%
2,724,083
+19,800
+0.7% +$227K
EVH icon
55
Evolent Health
EVH
$654M
$24.9M 0.48%
4,580,458
+1,031,845
+29% +$9.22M
HCA icon
56
HCA Healthcare
HCA
$82.3B
$24.5M 0.48%
272,966
+20,338
+8% +$2.63M
SGMO
57
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$24.5M 0.48%
3,850,000
– –
WVE icon
58
Wave Life Sciences
WVE
$1.12B
$24.4M 0.47%
2,602,858
+200,000
+8% +$1.7M
TFX icon
59
Teleflex
TFX
$5.96B
$22.9M 0.44%
78,333
+3,614
+5% +$1.26M
PACB icon
60
Pacific Biosciences
PACB
$447M
$22.6M 0.44%
7,378,791
+1,644,482
+29% +$6.73M
GWPH
61
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$22M 0.43%
250,966
+239,766
+2,141% +$25.4M
BIO icon
62
Bio-Rad Laboratories Class A
BIO
$8.15B
$21.9M 0.42%
62,373
+15,588
+33% +$5.73M
HOLX
63
DELISTED
Hologic
HOLX
$19.9M 0.39%
567,779
+306,000
+117% +$14.6M
MOH icon
64
Molina Healthcare
MOH
$11.7B
$17.9M 0.35%
128,206
-2,413
-2% -$323K
PODD icon
65
Insulet
PODD
$11.4B
$17M 0.33%
102,350
+920
+0.9% +$168K
MASI
66
DELISTED
Masimo
MASI
$16.3M 0.32%
92,245
+13,196
+17% +$2.26M
ABMD
67
DELISTED
Abiomed Inc
ABMD
$15.7M 0.3%
108,072
+20,233
+23% +$3.36M
KZR
68
DELISTED
Kezar Life Sciences
KZR
$15.3M 0.3%
351,889
+196,822
+127% +$8.01M
HCM icon
69
HUTCHMED
HCM
$1.86B
$15.2M 0.29%
851,994
+34,177
+4% +$824K
HMSY
70
DELISTED
HMS Holdings Corp.
HMSY
$14.5M 0.28%
575,177
+57,800
+11% +$1.51M
GMED icon
71
Globus Medical
GMED
$10.5B
$14.4M 0.28%
338,067
+230
+0.1% +$11.4K
PEN icon
72
Penumbra
PEN
$12.5B
$13.3M 0.26%
82,139
+13,284
+19% +$2.24M
OMCL icon
73
Omnicell
OMCL
$2.09B
$12.9M 0.25%
196,136
-203
-0.1% -$16.2K
GKOS icon
74
Glaukos
GKOS
$9.21B
$12.7M 0.25%
412,623
+10,475
+3% +$537K
CVS icon
75
CVS Health
CVS
$137B
$12.6M 0.25%
212,981
+5,702
+3% +$381K
1 2
3
4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q1 2020 Portfolio in Review

As of Q1 2020, Bellevue Group held 232 positions worth $5.16B, down 18% from $6.31B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

Bellevue Group's Q1 2020 filing shows 16 new, 80 increased, 52 reduced and 17 closed positions. Its largest new stake was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M. The largest sale was Teladoc Health, an estimated $63.8M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 96% a quarter earlier, followed by Technology and Industrials.

  • Bellevue Group's largest Q1 2020 buy was Black Diamond Therapeutics: 1,330,000 shares worth $33.2M.
  • Bellevue Group added most to Fate Therapeutics in Q1 2020, an estimated $37.4M increase.
  • Bellevue Group's biggest Q1 2020 reduction was Teladoc Health, cutting an estimated $63.8M.
  • Bellevue Group fully exited Wright Medical Group Inc in Q1 2020, selling an estimated $17.1M.
  • Bellevue Group's ten largest holdings make up 41% of its $5.16B portfolio in Q1 2020.
  • Bellevue Group opened 16 new positions and closed 17 in Q1 2020.
  • Bellevue Group's portfolio value fell 18% quarter-over-quarter to $5.16B.

Based on Bellevue Group's 13F filing for Q1 2020, filed 14 May 2020.